Parkman Healthcare Partners LLC Has $24.49 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Parkman Healthcare Partners LLC raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 112.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 421,782 shares of the company’s stock after acquiring an additional 223,155 shares during the period. Keros Therapeutics comprises approximately 3.1% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 5th biggest holding. Parkman Healthcare Partners LLC owned about 1.04% of Keros Therapeutics worth $24,493,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after acquiring an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC lifted its position in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares during the last quarter. Darwin Global Management Ltd. boosted its stake in shares of Keros Therapeutics by 6.3% during the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after purchasing an additional 89,952 shares during the period. Holocene Advisors LP grew its holdings in shares of Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its stake in shares of Keros Therapeutics by 28.8% in the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock worth $17,311,000 after buying an additional 84,810 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $62.28 on Wednesday. The firm’s 50-day moving average price is $59.67 and its 200-day moving average price is $52.37. The company has a market capitalization of $2.52 billion, a PE ratio of -11.95 and a beta of 1.20. Keros Therapeutics, Inc. has a 1-year low of $27.31 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.33) EPS. Equities analysts anticipate that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KROS. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target for the company. Bank of America reduced their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and a consensus target price of $88.89.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.